

Director/PDMR Shareholding

Released : August 05, 2024

RNS Number : 2126Z
Destiny Pharma PLC
05 August 2024

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Director/PDMR Shareholding

Brighton, United Kingdom - 5 August 2024 - Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life-threatening infections, announces that it was notified on 2 August 2024 that on that same day, Sir Nigel Rudd, Chairman of the Company, purchased 1,240,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 2.5 pence.

Following this purchase, Sir Nigel Rudd's beneficial interest in the Company (together with his spouse) is 3,761,716 Ordinary Shares, representing 3.93 per cent of the total issued share capital.

For further information, please contact:

Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com

FTI Consulting
Ben Atwell / Simon Conway
+44 (0) 203 727 1000
destinypharma@fticonsulting.com

Shore Capital (Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The Company's drug development pipeline includes two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA and NTCD-M3, a microbiome-based biotherapeutic for the prevention of *C. difficile* infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US.

For further information on the company, please visit www.destinypharma.com

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is

disclosed in accordance with the company's obligations under Article 17 of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Sir Nigel Rudd
2.	Reason for the Notification	
a)	Position/status	Chairman
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 1 pence each
	Identification code	DEST GB00BDHSP575
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	2.5 pence 1,240,000 Ordinary Shares
d)	Aggregated information:	
	Aggregated volume	See 4c) above
	Price	
e)	Date of the transaction	2 August 2024
f)	Place of the transaction	London Stock Exchange, AIM market (XLON)

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLFEITDIEIS